Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O'Sullivan JM, Protheroe A, Sheehan D, Srihari N, Parmar MK; STAMPEDE investigators. James ND, et al. Among authors: thalmann gn. Lancet Oncol. 2012 May;13(5):549-58. doi: 10.1016/S1470-2045(12)70088-8. Epub 2012 Mar 26. Lancet Oncol. 2012. PMID: 22452894 Free PMC article. Clinical Trial.
Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
MacLennan S, Azevedo N, Duncan E, Dunsmore J, Fullwood L, Lumen N, Plass K, Ribal MJ, Roobol MJ, Nieboer D, Schouten N, Skolarus TA, Smith EJ, N'Dow J, Mottet N, Briganti A; Pan-European National Urological Society IMAGINE Collaborative (see Supplemental material for group members affiliations):. MacLennan S, et al. Eur Urol. 2023 May;83(5):393-401. doi: 10.1016/j.eururo.2022.12.031. Epub 2023 Jan 11. Eur Urol. 2023. PMID: 36639296 Free article.
Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels.
Mertens LS, Bruins HM, Contieri R, Babjuk M, Rai BP, Puig AC, Escrig JLD, Gontero P, van der Heijden AG, Liedberg F, Martini A, Masson-Lecomte A, Meijer RP, Mostafid H, Neuzillet Y, Pradere B, Redlef J, van Rhijn BWG, Rouanne M, Rouprêt M, Sæbjørnsen S, Seisen T, Shariat SF, Soria F, Soukup V, Thalmann G, Xylinas E, Mariappan P, Alfred Witjes J. Mertens LS, et al. Eur Urol Oncol. 2024 Jun 20:S2588-9311(24)00141-X. doi: 10.1016/j.euo.2024.05.010. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38906795
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
Alfred Witjes J, Max Bruins H, Carrión A, Cathomas R, Compérat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, Mertens LS, Meijer RP, Milowsky MI, Neuzillet Y, Panebianco V, Redlef J, Rink M, Rouanne M, Thalmann GN, Sæbjørnsen S, Veskimäe E, van der Heijden AG. Alfred Witjes J, et al. Among authors: thalmann gn. Eur Urol. 2024 Jan;85(1):17-31. doi: 10.1016/j.eururo.2023.08.016. Epub 2023 Oct 17. Eur Urol. 2024. PMID: 37858453 Review.
Corrigendum to "A 2-center review of histopathology of variants of upper urinary tract urothelial carcinoma and their impact on clinical outcomes" [Urologic Oncology: Seminars and Original Investigations Volume 42 (2024) 333.e15-333.e20].
Giudici N, Schoch A, Genitsch V, Rodriguez-Calero A, Thalmann GN, Seiler R. Giudici N, et al. Among authors: thalmann gn. Urol Oncol. 2024 Nov 22:S1078-1439(24)00749-X. doi: 10.1016/j.urolonc.2024.11.016. Online ahead of print. Urol Oncol. 2024. PMID: 39580343 No abstract available.
Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trial.
Zwahlen DR, Schröder C, Holer L, Bernhard J, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Martin Putora P, Papachristofilou A, Schär C, Hayoz S, Sumila M, Zaugg K, Guckenberger M, Ost P, Giovanni Bosetti D, Reuter C, Gomez S, Khanfir K, Beck M, Thalmann GN, Aebersold DM, Ghadjar P. Zwahlen DR, et al. Among authors: thalmann gn. Clin Transl Radiat Oncol. 2024 Apr 25;47:100786. doi: 10.1016/j.ctro.2024.100786. eCollection 2024 Jul. Clin Transl Radiat Oncol. 2024. PMID: 38706726 Free PMC article.
Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31].
Alfred Witjes J, Bruins HM, Carrión A, Cathomas R, Compérat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, Mertens LS, Meijer RP, Milowsky MI, Neuzillet Y, Panebiaco V, Redlef J, Rink M, Rouanne M, Thalmann GN, Sæbjørnsen S, Veskimäe E, Mariappan P, van der Heijden AG. Alfred Witjes J, et al. Among authors: thalmann gn. Eur Urol. 2024 Jun;85(6):e180. doi: 10.1016/j.eururo.2024.03.002. Epub 2024 Mar 15. Eur Urol. 2024. PMID: 38492977 No abstract available.
293 results